Increased Lifespan of Leukemic Mice Treated with Drugs Related to (–)-Emetine
| Autor: | W.R. Jondorf, N.H. Greenberg, J.A.R. Mead, B.J. Abbott |
|---|---|
| Rok vydání: | 1971 |
| Předmět: |
Time Factors
Chemical Phenomena Mouse Leukemia Emetine medicine.medical_treatment Mice Inbred Strains Pharmacology Mice Alkaloids Drug Discovery medicine Animals Neoplasm Pharmacology (medical) Leukemia L1210 Entameba histolytica Chemotherapy business.industry Dosing regimen General Medicine medicine.disease Chemistry Infectious Diseases Oncology Immunology Female business Injections Intraperitoneal medicine.drug |
| Zdroj: | Chemotherapy. 16:109-129 |
| ISSN: | 1421-9794 0009-3157 |
| DOI: | 10.1159/000220718 |
| Popis: | The lifespan of mice bearing ascitic leukemia L1210 could be prolonged by treatment with (-)-emetine dihydrochloride. Optimal dosage schedules required emetine administration daily for 5 days (QD, day 1–5) or intermittently on every 4th day. (Q4D, day 1, 5, 9). Compounds related to (-)-emetine which are active in other biological systems, having the correct stereospecific structure at the C-1′ position in the molecule, a secondary amine structure at N-2′ and an ethyl-group substituent at C-3 were also effective in prolonging the survival time of L1210 leukemic mice. The effective compounds were (-)-cephaeline, (±)-2,3-dehydroemetine, (-)-2,3-dehydroemetine, (-)-tubulosine and (-)-O-methyltubulosine. In contrast, (-)-isoemetine and several derivatives of (±)-2,3-dehydroemetine, lacking the critical configuration at C-1′ or substitution at the N-2′ and C-3 positions in the molecule, were inactive in the mouse leukemia system, when administered according to the Q4D, day 1, 5, 9 schedule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|